In our present study, we enrolled 236 HER2-positive breast cancer patients with age ≥ 60 years disease and patients with aged ≥ 70 years (21/41, 51.2%) or T1a-b tumors (14/27, 51.9%) were more likely to be recommended to receive PH treatment. This evidence concerns the gene ERBB2 and breast cancer.